Kyverna Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2023 Dec2024
Operating Activities
Net Income -60.31M-127.39M
Depreciation and Depletion 0.90M1.20M
Share-based Compensation 2.22M8.36M
Gains from Investment Securities 1.85M3.80M
Cash from Operations -52.41M-114.30M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 1.11M7.66M
Depreciation & Amortization (CF) 1.71M2.13M
Change in Working Capital
Change in Account Payables 4.08M0.74M
Change in Accured Expenses 1.40M2.07M
Other Working Capital Changes -1.68M-2.40M
Investing Activities
Capital Expenditures 0.62M2.21M
Change in Acquisitions & Divestments 46.68M331.30M
Cash from Investing Activities -8.79M-160.90M
Financing Activities
Other financing activities 1.65M3.36M
Cash from Financing Activities 58.12M337.11M
Additional items
Change in Cash -3.08M61.96M
Free Cash Flow -53.03M-116.50M
Net Cash Flow -3.08M61.91M